News Archive

A pair of Baltimore teams focused on medication use are joining forces in the quest to ensure patients follow their prescribed plans.

Tech company emocha Mobile Health and the Baltimore-based University of Maryland School of Pharmacy’s Center for Innovative Pharmacy Solutions are collaborating to offer a medication review that combines pharmacists and a mobile app. This will be offered as emocha expands to hospitals, health systems and health insurers, said CEO Sebastian Seigeur.

“This is now our standard,” he said.

Image: Telehealth at the University of Maryland School of Pharmacy’s eHealth Center. (Courtesy photo)

NextGen Venture Partners reported Tuesday that it raised more than $42 million for its second fund, nearly double its initial haul three years ago.

The $42.68 million in new funding comes about a year after the venture firm first indicated plans to raise a fund, according to a Securities and Exchange Commission filing. Though, those efforts were delayed by its acquisition in early 2018 by Baltimore investment giant Brown Advisory. While Tuesday’s filing lists Brown Advisory CEO Michael Hankin as the top executive, NextGen co-founders Dan Mindus and Brett Gibson both remain managing partners, per the website, and still work in the D.C. area, according to their LinkedIn profiles.

As of yesterday, the XBI biotech index has not only reversed last month’s slump but reached the full-year high it set in April. And that’s despite the fact that drug pricing rhetoric has hardly subsided, and next year’s presidential election remains as unpredictable as ever.

Image: https://mailchi.mp

Venture capital has something of a reputation as a boys’ club, but there are women making their mark in this field. In particular, five women have been singled out for their contributions to the life sciences industry.

Bio Buzz selected five women venture capitalists who are considered “trailblazing investors shaping the future of life science investing” in the BioCapital Hotbed Community, which includes Delaware, Maryland, Virginia and Washington, D.C.

A consortium of leaders from Boston’s biggest research institutions are joining forces on advancing biological manufacturing and innovation. 

Executives from Harvard University, the Massachusetts Institute of Technology, Fujifilm Diosynth Biotechnologies, GE Healthcare Life Sciences and Alexandria Real Estate Equities will serve as the board of directors of a planned $50M center of advanced biological innovation and manufacturing, the group announced Monday.

Image: Wikimedia Commons/Joseph Williams Harvard University’s Widener Library

BETHESDA, Md., Oct. 14, 2015 /PRNewswire-USNewswire/ — The National Foundation for Cancer Research (NFCR) today announced the expansion of its Scientific Advisory Board. The NFCR Scientific Advisory Board includes Webster Cavenee, PhD, Chair; Frederick W. Alt, PhD; Ruggero De Maria, PhD; Kanaga Sabapathy, PhD; and Peter Vogt, PhD.

The mission of the NFCR Scientific Advisory Board is to provide scientific, strategic, and clinical guidance and direction for NFCR basic science and translational research programs. Directed by Webster Cavenee, PhD, the NFCR Scientific Advisory Board is comprised of leaders in cancer research who have made significant breakthroughs in the diagnosis and treatment of cancer, scientists who are committed to furthering NFCR’s unwavering commitment to funding research that will cure cancer—all types of cancer.

Greetings!

We would like to invite you to a special event to join other industry leaders and peers to celebrate a year of growth within our entrepreneurial ecosystem and the greater Biohealth Capital Region.

Several of the region’s top startup executives will participate in an engaging discussion and share the lessons they have learned along their journeys in building their past and current companies.

Greetings!

We would like to invite you to a special event to join other industry leaders and peers to celebrate a year of growth within our entrepreneurial ecosystem and the greater Biohealth Capital Region.

Several of the region’s top startup executives will participate in an engaging discussion and share the lessons they have learned along their journeys in building their past and current companies.

Headwinds ranging from an expected renewal of political wrangling over the price of prescription drugs to increasing pressure on sales of established treatments have largely, but not entirely, kept pharmaceutical companies from enjoying the increases of their biotech counterparts, as reflected in the share prices of exchange-traded funds (ETFs) consisting of pharma equities.